[1]ohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry (2004) 49:753–60. 10.1177/070674370404901106
[2]McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al.. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. (2005) 80:19–32. 10.1016/j.schres.2005.07.014
[3]Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 187:537–43. 10.1192/bjp.187.6.537
[4]Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 302:1765–73. 10.1001/jama.2009.1549
[5]Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. (2005) 150:1115–21. 10.1016/j.ahj.2005.02.007
[6]Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J. Clin. Psychiatry (2016) 77(Suppl. 2):8–11. 10.4088/JCP.14074su1c.02
[7]Gold SM, Dziobek I, Sweat V, Tirsi A, Rogers K, Bruehl H, et al.. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia (2007) 50:711–9. 10.1007/s00125-007-0602-7
[8]Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. (2004) 72:29–39. 10.1016/j.schres.2004.09.007
[9]Keefe RS. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. J Clin Psychiatry (2014) 75(Suppl. 2):8–13. 10.4088/JCP.13065su1.02
[10]Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res. (1991) 5:123–34. 10.1016/0920-9964(91)90039-T
[11]Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. In: Geyer MA, Gross G. editors. Novel Antischizophrenia Treatments. Berlin; Heidelberg, Springer Berlin Heidelberg; (2012). p. 11–37.
[12]Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. (2005) 8:457–72. 10.1017/S146114570500516X
[13]Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. (1999) 25:233–55. 10.1093/oxfordjournals.schbul.a033376
[14]Goozee R, Reinders AA, Handley R, Marques T, Taylor H, O'Daly O, et al.. Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: a functional MRI study. Schizophr Res. (2016) 173:174–81. 10.1016/j.schres.2015.02.023
[15]Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, et al.. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. CNS Drugs (2012) 26:975–82. 10.1007/s40263-012-0003-4
[16]
Johnsen E, Jorgensen HA, Kroken RA, Loberg EM. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial. Eur Psychiatry (2013) 28:174–84. 10.1016/j.eurpsy.2011.10.003
Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, et al.. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatr Clin Neurosci. (2007) 257:360–70. 10.1007/s00406-007-0739-x
Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando ML, et al.. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res. (2007) 96:146–55. 10.1016/j.schres.2007.08.002
Urben S, Baumann P, Barcellona S, Hafil M, Preuss U, Peter-Favre C, et al.. Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial. Psychiatr Q. (2012) 83:311–24. 10.1007/s11126-011-9201-3
[17]
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al.. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 64:633–47. 10.1001/archpsyc.64.6.633
Heinrichs RW. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 64:631–2. 10.1001/archpsyc.64.6.631
Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry (2004) 55:1013–22. 10.1016/j.biopsych.2004.01.027
Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—A meta-analysis of randomized clinical trials. Acta Psychiatr Scand. (2015) 131:185–96. 10.1111/acps.12374
[18]
Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, et al.. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol. (2006) 9:135–45. 10.1017/S1461145705005924
Joshua N, Gogos A, Rossell S. Executive functioning in schizophrenia: a thorough examination of performance on the Hayling Sentence Completion Test compared to psychiatric and non-psychiatric controls. Schizophr Res. (2009) 114:84–90. 10.1016/j.schres.2009.05.029
Spagna A, Dong Y, Mackie MA, Li M, Harvey PD, Tian Y, et al.. Clozapine improves the orienting of attention in schizophrenia. Schizophr Res. (2015) 168:285–91. 10.1016/j.schres.2015.08.009
Remillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res. (2005) 80:99–106. 10.1016/j.schres.2005.07.026
[19]Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry (2009) 9:44. 10.1186/1471-244X-9-44
[20]Keefe RS. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness. J Clin Psychiatry (2014) 75(Suppl. 2):8–13. 10.4088/JCP.13065su1.02
[21]
Addington J, Saeedi H, Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophr Res. (2005) 78:35–43. 10.1016/j.schres.2005.05.008
Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry (1999) 156:1342–8.
[22]
Rund B. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull. (1998) 24:425–35. 10.1093/oxfordjournals.schbul.a033337
[23]
Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N. Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract. (2015) 21:190–7. 10.1097/PRA.0000000000000065
Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al.. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. Schizophr Res. (2014) 158:134–41. 10.1016/j.schres.2014.06.035
[24]
Takeuchi H. [Optimal antipsychotic dose and dosing interval in the treatment of schizophrenia]. Seishin Shinkeigaku Zasshi (2015) 117:562–7.
Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al.. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. (2013) 39:993–8. 10.1093/schbul/sbt090
Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, et al.. Cognition and dopamine D2 receptor availability in the striatum in older patients with schizophrenia. Am J Geriatr Psychiatry (2017) 25:1–10. 10.1016/j.jagp.2016.08.001
Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, et al.. Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry (2015) 72:927–34. 10.1001/jamapsychiatry.2015.0891
[25]Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al.. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. Schizophr Res. (2014) 158:134–41. 10.1016/j.schres.2014.06.035
[26]Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull. (2011) 37:1318–26. 10.1093/schbul/sbq057
[27]Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, et al.. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol. (2009) 24:565–73. 10.1002/hup.1057
[28]Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, et al.. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophr Res. (2015) 161:351–6. 10.1016/j.schres.2014.11.018
[29]
Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, et al.. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol. (1999) 19:209–21. 10.1097/00004714-199906000-00003
Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry (2002) 14:123–9. 10.3109/10401230209149099
Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J, et al.. A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatr Res. (2004) 129:159–69. 10.1016/j.psychres.2004.07.008
[30]Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol. (2012) 26:1167–74. 10.1177/0269881112447988
Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. (2011) 10:751–65. 10.1517/14740338.2011.579899
[31]
DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 10:52–77. 10.1002/j.2051-5545.2011.tb00014.x
Zipursky RB, Christensen BK, Daskalakis Z, Epstein I, Roy P, Furimsky I, et al.. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Can J Psychiatry (2005) 50:462–9. 10.1177/070674370505000806
Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al.. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. (2008) 99:13–22. 10.1016/j.schres.2007.10.022
Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Teran JM, et al.. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol. (2008) 28:289–95. 10.1097/JCP.0b013e318172b8e6
Correll CU. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry (2011) 72:e26. 10.4088/JCP.9101tx5c
[32]Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al.. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res. (2008) 99:13–22. 10.1016/j.schres.2007.10.022
[33]Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al.. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a danish population-based cohort study. Am J Psychiatry (2017) 174:686–94. 10.1176/appi.ajp.2016.16040442
[34]Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol Endocrinol Metabol. (2018). 10.1152/ajpendo.00164.2018
[35]Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease—A non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry (2014) 5:137. 10.3389/fpsyt.2014.00137
[36]Malan-Müller S, Kilian S, van den Heuvel LL, Bardien S, Asmal L, Warnich L, et al.. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophr Res. (2016) 170:1–17. 10.1016/j.schres.2015.11.011
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2008) 63:801–8. 10.1016/j.biopsych.2007.09.024
Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. (2012) 36:764–85. 10.1016/j.neubiorev.2011.12.005
Üçok A, Alpsan H, Çakir S, Saruhan-Direskeneli G. Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. Am J Med Gen Part B Neuropsychiatr Genet. (2007) 144B:704–7. 10.1002/ajmg.b.30463
Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Purcell S, et al.. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res. (2007) 92:181–8. 10.1016/j.schres.2007.01.003
[37]
Takayanagi Y, Cascella NG, Sawa A, Eaton WW. Diabetes is associated with lower global cognitive function in schizophrenia. Schizophr Res. (2012) 142:183–7. 10.1016/j.schres.2012.08.034
Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, et al.. Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disorders (2014) 16:422–31. 10.1111/bdi.12200
[38]Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N. Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract. (2015) 21:190–7. 10.1097/PRA.0000000000000065
[39]
Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, et al.. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev. (2010) 9:399–417. 10.1016/j.arr.2010.04.007
Walker J, Harrison F. Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer's disease: impacts on cognitive decline. Nutrients (2015) 7:7332–57. 10.3390/nu7095341
[40]Boyer L, Richieri R, Dassa D, Boucekine M, Fernandez J, Vaillant F, et al.. Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatr Res. (2013) 210:381–6. 10.1016/j.psychres.2013.06.020
[41]Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N. Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract. (2015) 21:190–7. 10.1097/PRA.0000000000000065
[42]Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, et al.. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res. (2012) 142:171–6. 10.1016/j.schres.2012.09.019
[43]Krakowski M, Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res. (2011) 130:27–33. 10.1016/j.schres.2011.04.005
[44]
Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, et al.. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry (2015) 172:579–85. 10.1176/appi.ajp.2015.14050673
Ter Horst KW, Lammers NM, Trinko R, Opland DM, Figee M, Ackermans MT, et al. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Sci Transl Med. (2018) 10:eaar3752 10.1126/scitranslmed.aar3752
Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, et al.. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. Int J Neuropsychopharmacol. (2015) 18:pyv014. 10.1093/ijnp/pyv014
Lee Y, Kroemer NB, Oehme L, Beuthien-Baumann B, Goschke T, Smolka MN. Lower dopamine tone in the striatum is associated with higher body mass index. Eur Neuropsychopharmacol. (2018) 28:719–31. 10.1016/j.euroneuro.2018.03.009
Wilcox CE, Braskie MN, Kluth JT, Jagust WJ. Overeating behavior and striatal dopamine with 6-[F]-fluoro-L-m-tyrosine PET. J Obes. (2010) 2010:909348 10.1155/2010/909348
Caravaggio F, Borlido C, Wilson A, Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [11C]-(+)-PHNO positron emission tomography: a pilot study. Clin Chim Acta (2015) 449:60–2. 10.1016/j.cca.2015.03.020
[45]
Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring HU. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev. (2016) 96:1169–209. 10.1152/physrev.00032.2015
Spinelli M, Fusco S, Mainardi M, Scala F, Natale F, Lapenta R, et al.. Brain insulin resistance impairs hippocampal synaptic plasticity and memory by increasing GluA1 palmitoylation through FoxO3a. Nat Commun. (2017) 8:2009. 10.1038/s41467-017-02221-9
Ramos-Rodriguez JJ, Molina-Gil S, Ortiz-Barajas O, Jimenez-Palomares M, Perdomo G, Cozar-Castellano I, et al.. Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models. PLoS ONE (2014) 9:e89229. 10.1371/journal.pone.0089229